Literature DB >> 26847247

Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease.

Fleur Cohen-Aubart1, Philippe Maksud2, David Saadoun3, Aurélie Drier4, Frédéric Charlotte5, Philippe Cluzel6, Zahir Amoura1, Julien Haroche1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26847247     DOI： 10.1182/blood-2015-09-672667

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  12 in total

Review 1.  Erdheim-Chester disease: a rapidly evolving disease model.

Authors:  Francesco Pegoraro; Matthias Papo; Valerio Maniscalco; Frédéric Charlotte; Julien Haroche; Augusto Vaglio
Journal:  Leukemia       Date:  2020-06-26       Impact factor: 11.528

Review 2.  Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.

Authors:  Matthias Papo; Fleur Cohen-Aubart; Ludovic Trefond; Adeline Bauvois; Zahir Amoura; Jean-François Emile; Julien Haroche
Journal:  Curr Oncol Rep       Date:  2019-05-21       Impact factor: 5.075

3.  Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease.

Authors:  Eli L Diamond; Omar Abdel-Wahab; Benjamin H Durham; Ahmet Dogan; Neval Ozkaya; Lynn Brody; Maria Arcila; Christian Bowers; Mark Fluchel
Journal:  Blood       Date:  2016-08-17       Impact factor: 22.113

Review 4.  Erdheim-Chester Disease: a Concise Review.

Authors:  Matthias Papo; Jean-François Emile; Thiago Trovati Maciel; Pierre Bay; Alistair Baber; Olivier Hermine; Zahir Amoura; Julien Haroche
Journal:  Curr Rheumatol Rep       Date:  2019-12-05       Impact factor: 4.592

5.  Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.

Authors:  Kenneth McClain
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 6.  Histiocytic disorders.

Authors:  Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen
Journal:  Nat Rev Dis Primers       Date:  2021-10-07       Impact factor: 65.038

7.  Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment.

Authors:  Fréderic Franconieri; Samuel Deshayes; Hubert de Boysson; Salim Trad; Nicolas Martin Silva; Benjamin Terrier; Boris Bienvenu; Françoise Galateau-Sallé; Jean-François Emile; Alison C Johnson; Achille Aouba
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

Review 8.  Histiocytosis.

Authors:  Jean-François Emile; Fleur Cohen-Aubart; Matthew Collin; Sylvie Fraitag; Ahmed Idbaih; Omar Abdel-Wahab; Barrett J Rollins; Jean Donadieu; Julien Haroche
Journal:  Lancet       Date:  2021-04-23       Impact factor: 202.731

9.  Erdheim-Chester Disease Involving Lymph Nodes and Liver Clinically Mimicking Lymphoma: A Case Report.

Authors:  Yeoun Eun Sung; Yoon Seo Lee; Jieun Lee; Kyo Young Lee
Journal:  J Pathol Transl Med       Date:  2017-12-27

10.  Neurological manifestations of Erdheim-Chester Disease.

Authors:  Louisa C Boyd; Kevin J O'Brien; Neval Ozkaya; Tanya Lehky; Avner Meoded; Bernadette R Gochuico; Fady Hannah-Shmouni; Avindra Nath; Camilo Toro; William A Gahl; Juvianee I Estrada-Veras; Rahul H Dave
Journal:  Ann Clin Transl Neurol       Date:  2020-03-29       Impact factor: 4.511
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.